Stock picks to buy, 22 stocks still below pre-pandemic levels: Goldman - Business Insider
- Meanwhile, some smaller and more economically sensitive stocks have yet to reach their pre-pandemic levels as earnings have stalled.
- Hopes for a strong economic return got another shot in the arm when Democrats won two runoff Senate races in Georgia.
- Goldman Sachs consequently upped its economic and earnings estimates for the year.
- To help investors take advantage of the momentum cyclical stocks are expected to see, Kostin and his team put together a list of 22 stocks that meet the following two criteria: a share price still below the February 19 peak and expected earnings that are higher than those in 2019.
- The 22 stocks are listed below in ascending order of how far below February 19 levels their prices sat as of January 14.
- Get the latest Goldman Sachs stock price here.
Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
- Eli Lilly & Co. said its antibody-based drug prevented Covid-19 among many residents and staff of nursing homes and assisted-living facilities, results that point to the drug complementing vaccines while inoculations increase.
- The drug, called bamlanivimab, reduced the risk of both staff and residents getting sick with Covid-19 by about 57% compared with a placebo, Lilly said Thursday.
- The effect was more pronounced among residents, the company said, an 80% reduction in risk of Covid-19.
- The findings signal the potential for a new preventive weapon that could augment the fledgling Covid-19 vaccination effort to stem the pandemic.
- Lilly said it would ask U.S. health regulators to widen the drug’s authorized use to include protecting people in long-term-care facilities where someone has recently been diagnosed with Covid-19.
- Lilly disclosed the data in a news release and said it plans to publish full results in a peer-reviewed medical journal.
Biden’s Agenda Depends on Success in Curbing Covid-19 Pandemic
- WASHINGTON—President Biden’s success in achieving some of his biggest policy objectives—curbing climate change, expanding health coverage and overhauling immigration laws—will depend in large part on his success in combating the coronavirus pandemic, which he sought to jump-start Thursday with a national road map and a series of executive orders.
- Health experts both inside and outside the new administration agree that while accelerating vaccinations will help restore normalcy and spur momentum for Mr. Biden’s broader political agenda, the opposite is also true: Failing to slow the spread of Covid-19 could also overshadow his presidency.
- Mr. Biden’s national strategy announced Thursday is part of a blizzard of activity to curb the virus in his first 100 days, including a federal mask mandate, the administration of 100 million vaccines, the establishment of 100 federally supported vaccination centers, and reopening of most kindergarten-through-eighth-grade schools.
How worried should we be about the new coronavirus variants?
- THE rise and spread of new variants of the coronavirus are seen as ushering in a dangerous new phase of the covid-19 pandemic.
- But from the virus’s perspective, nothing has changed.
- It is just doing what comes naturally to viruses: evolving.
- Existing subscribers, please log in with your email address to link your account access.
Slow Covid Vaccine Distribution Adds to Tokyo Olympics Woes
- Organizers of the Tokyo Olympics face a long list of obstacles as they attempt to carry off the postponed Games in six months—and the alarming rise in Covid cases around the world recently is only one of them.
- Potentially bigger hurdles include the need to speed up Covid-19 vaccinations globally and in the U.S. and convincing a skeptical Japanese public to accept vaccines and welcome thousands of visitors from around the globe.
- The International Olympic Committee and organizers in Japan last March delayed the Games from 2020 to 2021, a move that came about four months before the event was set to begin.
- Although Olympic organizers have said they won’t require vaccines for fans and athletes coming to the Games, Japanese Prime Minister Yoshihide Suga has said he wants almost everyone in Japan vaccinated by the Olympics’ July 23 start.
COVID vaccine is 'nothing like Tuskegee': Black scientist on FDA panel - Business Insider
- A Kaiser Health News analysis found that while Black Americans are disproportionately affected by COVID-19, in some states their vaccination rates are two to three times lower than their white neighbors.
- In December, 35% of Black people said they probably or definitely wouldn't get the shot.
- But coronavirus vaccines have been developed in just 10 months, which "will go down probably as one of the greatest scientific achievements of this century," Hildreth, who's also the president and CEO of Meharry Medical College, said.
- Hildreth said the horror of Tuskegee prompted major changes in human research.
- Last, 10% of participants in the vaccine trials were Black, and 30% to 50% had underlying conditions like diabetes, asthma, obesity, and high blood pressure that disproportionately affect people of color.
New CDC Director Pledges to Speed Vaccination, Restore Trust in Agency
- Rochelle Walensky, the incoming director of the U.S. Centers for Disease Control and Prevention, said she will start her new job with a big to-do list: helping states fix Covid-19 vaccination programs and persuading exhausted Americans to wear masks and take other precautions.
- In an interview with The Wall Street Journal, Dr. Walensky said the agency will try to help people overcome doubts about Covid-19 vaccines and she vowed to increase public trust in the CDC.
- Dr. Walensky will take the helm of the CDC on Wednesday, as a highly transmissible mutant, or variant, of the novel coronavirus threatens to cause a new surge in infections in the next few weeks.
- Meanwhile, the vaccination campaign to stop the pandemic is off to a slow start, and surveys show many people in the U.S. are hesitant to get vaccinated.
Scott Morrison leaves open chance of international travel before 2022
- The federal government could seek a more ambitious timeline for reopening Australia's international borders, promising a "week by week" review of medical advice and rollout of COVID-19 vaccines – conditions critical to ending travel bans and new pain for the tourism sector before 2022.
- In contrast with the prediction of Health Department secretary Brendan Murphy that an end to travel restrictions was off the agenda until 2022, Prime Minister Scott Morrison said plans for another 12 months of restrictions and hotel quarantine rules could be reconsidered.
- Professor Murphy said on Monday the continuing risk of virus transmission, even after vaccination, left border closures as "a big open question".
- Former Health Department boss Jane Halton, who led the government's review of hotel quarantine arrangements, said she believed existing isolation rules were effective at stopping spread and could remain in place for 12 months, if necessary.
New York Gov. Cuomo asks Pfizer to bypass feds, sell vaccine to state - Business Insider
- New York Gov. Andrew Cuomo called on pharmaceutical company Pfizer to sell doses of its coronavirus vaccine directly to New York state, in the hopes of accelerating a process that has languished in recent weeks.
- The request would require Pfizer to circumvent the federal government's Operation Warp Speed — a campaign to produce and distribute some 300 million doses to Americans in an effort to end the pandemic — and deal directly with Cuomo's state administration.
- As of Monday evening, more than 645,000 vaccines had been distributed in the state of New York, according to the Coronavirus Resource Center at Johns Hopkins University.
- As roll-outs of coronavirus vaccines including those created by pharmaceuticals companies Pfizer and Moderna have languished in the US in recent weeks, Tedros hasn't been the only world leader to shine a light on the crisis.
Vaccines and COVID-19: The latest hopeful research
- New, and possibly more contagious, variants of SARS-CoV-2 — which is the virus that causes COVID-19 — are emerging in countries around the world.
- In this Hope Behind the Headlines feature, we look at what experts have to say about whether or not currently authorized vaccines are likely to protect us against new SARS-CoV-2 variants.
- When speaking to Medical News Today earlier this month, both Pfizer and the NIAID declared that there is no reason to suspect that their vaccines would not work against the SARS-CoV-2 variant identified in the U.K. Both Pfizer-BioNTech and Moderna-NIAID, whose vaccines are currently authorized for use in the U.S. and U.K., offer mRNA vaccines.
- Other scientists have also noted that at least some of the COVID-19 vaccines that have gained authorization around the world should be adaptable so as to remain effective against emerging variants of SARS-CoV-2.